May 6, 2013
- IMI's EU-AIMS (European Autism Interventions - A Multicentre Study for Developing New Medications) project is making breakthroughs in research into autism spectrum disorder (ASD), that are set to make a real difference to the lives of people with autism and their families. ASD affects around one in a hundred children, but still has no effective drug treatments. ASD symptoms include problems with social interactions, behaviour, co-ordination, language and communication. These range from mild to...
May 5, 2013
GlaxoSmithKline plc (GSK) announced a funding injection of up to £5m from the Wellcome Trust to support its open approach to discovering and developing urgently needed new treatments for diseases of the developing world. The funding will move early-stage research to the next level, to find new medicines for diseases such as TB, malaria,...
May 3, 2013
- The European Medicines Agency's website, ema.europa.eu, will be unavailable between 9.00am and 5.30pm on Saturday 4 May 2013, due to essential maintenance.
- The first details of the planned reorganisation of the European Medicines Agency (EMA) have been announced.
- A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer a step closer, researchers said at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients....
May 2, 2013
- A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer a step closer, researchers said at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.
- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes